RE: Let be honest for a moment.28 Nov 2020 22:20
HarChris, agreed time to get back to Novacyt and why we are here ...... to make money. At the risk of sounding vulgar that is why we invest and are invested. To be frank it would be great if someone could summarise where NCYT is currently with products, contracts and prospects. During October and November we waited for NPT trials to be completed with the anticipation that DHSC contracts would be coming our way to propel us to midcap status. The events as unfolded so far has focused on LFT mass testing in Liverpool. We are wondering if LFT is now in our arsenal. - maybe but no news on this yet. We have had the very low key launch of Versalab, which has not as yet captured investor excitement. There is talk of Avantor hook up in US. Details remain sketchy. Lots going on in the background with potential cash pile building up and will not be reflected until this is published. We seem to be swimming in a sea of the information that is not translating to sp increase. So it seems we don’t really know, HMG continues to try to justify cheap alternatives which would be reasonable if they were reliable. Very unclear how this will unfold. Q16 and Q32 well embedded and we hope to get Phase 2 contract award early December. Q16 and Q32 production run increased 5 fold! Next generation of PCR eliminating another stage in processing. The range of products is truly impressive especially if the tests can be
conducted using Q16 and Q32. Then there is the contract that spans 4 years covering a range of services. It does seem NCYT needs a consortium approach to capture this prize. So much going on and much more that we do not know. The wait for this company to take the big stage is agonising. Re-rate is not far off.
GLA and stay safe.
Sign In
Follow the stocks
